Bizarre Patents
Process For Propelling Foodstuffs or the Like into a Crowd
A method of launching foodstuffs into a crowd for promotional and entertainment purposes.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187584 | Human tumor necrosis factor-α mutants The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effect... | 05/29/2012 |
| 8173117 | Mouse CX3C chemokine polypeptides Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. ... | 05/08/2012 |
| 8124065 | Cytokine Protein Family The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class I... | 02/28/2012 |
| 8114394 | Use of IL-1 antagonists to treat gout Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) anta... | 02/14/2012 |
| 8101165 | Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released... | 01/24/2012 |
| 8084020 | Use of anti-CD1 antibodies for the modulation of immune responses The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, aller... | 12/27/2011 |
| 8067367 | Methods of increasing platelet and hematopoietic stem cell production A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed. | 11/29/2011 |
| 8043608 | Methods of using Fc-cytokine fusion proteins Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-ant... | 10/25/2011 |
| 8012464 | G-CSF-albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic ac... | 09/06/2011 |
| 8008254 | Methods and compositions for the repair and/or regeneration of damaged myocardium Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines are disclosed and claimed. ... | 08/30/2011 |
| 7993636 | Tumor necrosis factor-alpha mutants The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effect... | 08/09/2011 |
| 7972591 | Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered. ... | 07/05/2011 |
| 7964183 | Composition and dosage form comprising a particle formulation and suspending vehicle A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent. ... | 06/21/2011 |
| 7959907 | Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylcer... | 06/14/2011 |
| 7947265 | Fusion proteins and methods for modulation of immune response A fusion protein comprising GM-CSF and IL-15 is described. The fusion protein has unexpected immune suppressive properties and is useful in a variety of therapeutic applications. ... | 05/24/2011 |
| 7947264 | TGF-β3 mutants The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilizing substitution. The invention also pr... | 05/24/2011 |
| 7939056 | Interleukin-10 compositions for the treatment of adenocarcinomas The present invention is directed to methods for the treatment of adenocarcinomas that are characterized by the overexpression of a particular oncogene, Pim-1. The procedure involves administering a therapeutically effective amount of interleukin-10 that has been co... | 05/10/2011 |
| 7939057 | Methods and compositions for modulating the mobilization of stem cells Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use ... | 05/10/2011 |
| 7919077 | Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage for... | 04/05/2011 |
| 7906109 | Pharmaceutical composition comprising an active principal and sulphobetaine The present invention relates to the pharmaceutical composition comprising a non-detergent sulphobetaine (NDSB). ... | 03/15/2011 |
| 7901669 | Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing OSMRβ as a subunit, and applications thereof The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for activating in vitro and/o... | 03/08/2011 |
| 7892529 | Peptides for active anti-cytokine immunization Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... | 02/22/2011 |
| 7879319 | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is u... | 02/01/2011 |
| 7879318 | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The th... | 02/01/2011 |
| 7867481 | Method of treating anemia by administering IL-1ra The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) recep... | 01/11/2011 |
| 7824669 | In vivo stimulation of peripheral blood progenitor cells by granulocyte-macrophage colony stimulating factor (GM-CSF) cysteine muteins and their PEGylated variants The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues t... | 11/02/2010 |
| 7820154 | Use of IL-1 antagonists to treat gout Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) anta... | 10/26/2010 |
| 7790152 | Enhancer for antibody to lymphocytic tumors An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active in... | 09/07/2010 |
| 7785579 | Modified tumor necrosis factor Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not ... | 08/31/2010 |
| 7780959 | Feline granulocyte macrophage colony stimulating factor nucleic acid molecules The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine ... | 08/24/2010 |
| 7758852 | OX40R binding agents The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other mole... | 07/20/2010 |
| 7744862 | Production process of recombinant placental growth factor Process for extracting and purifying the recombinant Placental Growth Factor (PLGF) expressed in inducible prokaryotic expression systems comprising the following steps: I) fermentation of the bacterial cells, II) extraction and purification of the inclusion bodies,... | 06/29/2010 |
| 7740834 | Murine zcytor17 ligand polypeptides The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of... | 06/22/2010 |
| 7740833 | Therapeutic uses of chemokine variants Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammat... | 06/22/2010 |
| 7736637 | Use of TRAIL polypeptides to induce apoptosis A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL po... | 06/15/2010 |
| 7731945 | Immunotherapy for reversing immune suppression A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to end... | 06/08/2010 |
| 7713521 | MCP1 fusions The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered. ... | 05/11/2010 |
| 7708983 | Directional induction of immune response by co-administration of antigens with chemokines The present invention relates to compositions and methods of using same to direct an immune response thereby enhancing the efficacy of an antigen containing vaccine by combining a chemokine in conjunction with the vaccine, wherein the choice of the chemokine directs... | 05/04/2010 |
| 7708984 | Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, ex... | 05/04/2010 |
| 7700087 | Compounds and methods to inhibit or augment an inflammatory response Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided. For example, the invention provides peptides of no more than 15 amino acid residues which include chemokine peptide sequences and variant... | 04/20/2010 |
